Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860142 | 0.91 | ADORA1 (0.37) | ADORA1 | |
| SCHEMBL3229780 | 0.86 | ADORA1 (0.38) | ADORA1 | |
| SCHEMBL29068760 | 0.78 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL5245060 | 0.78 | ADORA1 (0.38) | ADORA1 | |
| SCHEMBL5369246 | 0.74 | P2RY14 (0.39) | ADORA1 | |
| SCHEMBL263892 | 0.73 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL769262 | 0.73 | ADORA1 (0.45) | ADORA1 | |
| SCHEMBL28533385 | 0.71 | ADORA1 (0.37) | ADORA1 | |
| SCHEMBL8329378 | 0.70 | ADORA1 (0.44) | ADORA1 | |
| SCHEMBL2510604 | 0.70 | ADORA1 (0.44) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018559-A1 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | ACIES BIO D.O.O. (SI) | 2024-01-18 | — | — | US | claimed |
| EP-4251745-A1 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | Acies Bio d.o.o. (SI) | 2023-10-04 | — | — | EP | claimed |
| WO-2022112509-A1 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | ACIES BIO D.O.O. (SI) | 2022-06-02 | — | — | WO | claimed |
| EP-4006139-A1 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | Acies Bio d.o.o. (SI) | 2022-06-01 | — | — | EP | claimed |
| EP-2601209-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | Bayer Intellectual Property GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016960-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | WO | claimed |
| US-20260146295-A1 | MULTIPLEXED FUEL ANALYSIS | ANDE CORPORATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-12529111-B2 | Multiplexed fuel analysis | ANDE CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | disclosed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | disclosed |
| US-12480166-B2 | Multiplexed fuel analysis | ANDE CORPORATION (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250346963-A1 | MULTIPLEXED FUEL ANALYSIS | ANDE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| US-20250320566-A1 | MULTIPLEXED FUEL ANALYSIS | ANDE CORPORATION | 2025-10-16 | — | — | US | disclosed |
| WO-2004018646-A2 | CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1379549-A2 | SEQUENCE OF THE PHOTORHABDUS LUMINESCENS STRAIN TT01 GENOME AND USES | INSTITUT PASTEUR (FR) | 2004-01-14 | — | — | EP | disclosed |
| US-6632935-B2 | Nucleotide sequences coding preferential protein for use in biological pest control | RIKEN (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030170845-A1 | Tetrahydrofolate metabolic enzymes | FAMODU OMOLAYO O (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003072602-A2 | PROTEIN COMPLEXES AND METHODS FOR THEIR USE | CELLZOME AG (DE) | 2003-09-04 | — | — | WO | disclosed |
| WO-2002094867-A2 | SEQUENCE OF THE PHOTORHABDUS LUMINESCENS STRAIN TT01 GENOME AND USES | INSTITUT PASTEUR (FR) | 2002-11-28 | — | — | WO | disclosed |
| US-6436657-B1 | CHIMERIC GENE ENCODING TETRAHYDROFOLATE METABOLIC ENZYME; INDENTIFYING ENZYME INHIBITORS AS HERBICIDES; PLANTS | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146295-A1 | MULTIPLEXED FUEL ANALYSIS | POLRMT, POLQ, POLH | ADORA1 1706/4885 |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | NPPA, TNNT2, SLC5A2 | ADORA1 3036/4885 |
| US-12529111-B2 | Multiplexed fuel analysis | POLRMT, POLM, POLQ | ADORA1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.